GLD Partners, LP

What GLD Partners, LP does

GLD Partners, LP is a Los Angeles-based private investment partnership founded in 2003 that operates as a life sciences-focused portfolio builder in the biotechnology sector. Rather than pursuing a traditional fund model, the firm acquires distressed and de-risked biotech assets and builds platform-driven biotech companies. Its strategy centers on capital-efficient acquisition of late-stage clinical programs with existing safety data and leveraging proprietary technologies through licensing arrangements.

The company's portfolio includes three principal assets as of October 2025. First, through a Chapter 11 Section 363 sale in the U.S. Bankruptcy Court for the Southern District of New York, GLD acquired Seelos Therapeutics' late-stage ketamine program for major depressive disorder (targeting a market projected to exceed $15 billion annually by 2035) and a trehalose program for rare neurodegenerative diseases (with orphan drug designation potential). GLD had previously acquired Seelos' senior secured debt, which provided negotiating leverage in the asset acquisition. Second, in October 2025, GLD launched Altagenics, a wholly-owned biotechnology subsidiary focused on drug discovery for muscle-wasting diseases (sarcopenia and cachexia), which leverages Heligenics' proprietary GigaAssay™ functional genomics platform capable of testing hundreds of thousands of protein variants in parallel.

GLD Partners generates value through clinical advancement and eventual commercialization of its acquired and launched programs rather than through traditional product sales or fee-based revenue. The firm operates with 1-10 employees and uses GlobeNewswire press releases and industry press coverage as its primary visibility channels. Daniel Gordon serves as Managing Director. There are no disclosed revenue figures, funding rounds, or pricing models in the available data, consistent with the firm's structure as a private investment partnership building long-term biotech equity value rather than generating near-term cash flow.

Name

GLD Partners, LP

Legal name

GLD Partners, LP

Website

https://gldlp.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

1–10 employees

Short description

GLD Partners is a Los Angeles-based private life sciences investment partnership that acquires distressed biotech assets and builds platform-driven biotech companies, with a current portfolio spanning CNS, rare neurodegenerative, and muscle-wasting disease programs.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Investment

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Portfolio Management and Investment Advice (523940)

SIC

Pharmaceutical Preparations (2834), Investment Advice (6282)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industries

Neurogenetics & Rare Neurologic Diseases (HLAKAIAO), Clinical Trials Authorization & Oversight (GCP) (HLAJADAF)

Keywords

• Life sciences investment
• Biopharmaceutical asset acquisition
• Drug development programs
• Alternative investments
• Biotech company creation

Headquarters

HQ city

Los Angeles

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Marketing channels2 records

Core offering

GLD Partners, LP is a private life sciences investment firm that acquires distressed and de-risked biopharmaceutical assets and builds platform-driven biotech companies. The firm targets CNS, rare disease, and muscle-wasting therapeutic areas, currently holding a Phase 3-ready ketamine program for major depressive disorder, a trehalose program for rare neurodegenerative diseases, and Altagenics (a biotech using Heligenics' GigaAssay™ platform for muscle-wasting disease drug discovery).

Product overview

GLD Partners, LP is a life sciences investment firm operating as a portfolio company builder. The company acquires distressed biotech assets through Chapter 11 proceedings and builds platform-driven biotech companies. Current portfolio includes: the ketamine program for major depressive disorder and trehalose program for rare neurodegenerative diseases (both acquired from Seelos Therapeutics), and Altagenics (newly launched company focused on muscle-wasting diseases using the GigaAssay™ functional genomics platform). The firm targets CNS, rare disease, and muscle-wasting therapeutic areas with capital-efficient development strategies.

Differentiator

Problem solved

Functional benefit

Products and services

• Altagenics A biotechnology company launched by GLD Partners focused on drug discovery for muscle-wasting diseases, leveraging Heligenics' proprietary GigaAssay™ functional genomics platform. Initially targeting sarcopenia and cachexia.
• Ketamine Program A late-stage ketamine clinical program targeting major depressive disorder (MDD), acquired from Seelos Therapeutics. GLD plans to advance this program into Phase 3 clinical trials.
• Trehalose Program A trehalose clinical program targeting rare neurodegenerative disorders, acquired from Seelos Therapeutics. Features orphan drug designation opportunities. GLD plans to advance this program into adaptive Phase 2/3 clinical trials.

Quantifiable outcome

• Global MDD therapeutics market projected to exceed $15 billion annually by 2035
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• Seelos Therapeutics, Inc.coreStrategic or Co-development Partner · 21 October 2025GLD Partners acquired select assets from Seelos Therapeutics through a Chapter 11 Section 363 sale in the U.S. Bankruptcy Court for the Southern District of New York. GLD had previously acquired Seelos' senior secured debt. Acquired assets include late-stage ketamine program for major depressive disorder and trehalose program for rare neurodegenerative disorders. GLD plans to advance both programs into Phase 3 and adaptive Phase 2/3 clinical trials respectively.
• HeligenicscoreTechnology or Integration · 7 October 2025GLD Partners launched Altagenics as a new biotech company leveraging Heligenics' proprietary GigaAssay™ platform for drug discovery. The platform enables testing hundreds of thousands of protein variants in parallel, representing a core technology for Altagenics' muscle-wasting disease programs targeting sarcopenia and cachexia. This represents GLD's strategy to build platform-driven biotech companies using licensed proprietary technology.

Recent moves5 records

Expansion highlights5 records

Direct peers

• Royalty Pharma: Royalty Pharma is the largest dedicated pharma royalty and alternative-investment firm, acquiring cash-flow interests in late-stage biopharma assets. Highly comparable to GLD's strategy of acquiring de-risked pharma assets through alternative transaction structures.
• Baker Bros. Advisors: Baker Bros. is a long-only biotech-focused investment firm that takes concentrated positions in life sciences companies. Directly comparable as a life sciences-focused alternative investment manager with similar late-stage asset underwriting expertise.
• BridgeBio Pharma: BridgeBio is a commercial-stage biotech company builder with a portfolio model across multiple therapeutic areas including CNS and rare disease. Comparable as a multi-program biotech builder, though structured as a public operating company rather than an LP.
• Perceptive Advisors: Perceptive Advisors is a life sciences-focused investment firm managing credit and equity strategies across biotech. Comparable as a private life sciences investment manager deploying capital into biotech assets.
• OrbiMed: OrbiMed is one of the largest dedicated healthcare investment firms globally, with venture, growth, and credit strategies across therapeutics. Comparable as a healthcare-focused alternative investment manager with deep biotech expertise.
• ARCH Venture Partners: ARCH Venture Partners creates and invests in biotech companies, often founding platform companies around proprietary technologies — directly comparable to GLD's launch of Altagenics around the licensed GigaAssay™ platform.
• RA Capital Management: RA Capital is a healthcare-focused investment manager that combines public equity and private investment, often participating in late-stage biotech rounds. Comparable as a dedicated life sciences alternative investment firm.
• Deerfield Management: Deerfield Management is a healthcare investment firm deploying capital across public equities, private debt, and venture. Comparable as a healthcare-focused alternative asset manager with multi-strategy biotech exposure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key highlights5 records

Customer concentration

• Xx.com/DanielGordonGLD
• Facebookfacebook.com/danielgordongld
• LinkedInlinkedin.com/company/daniel-gordon-gld

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GLD Partners, LP